To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves Opdivo for MSI-H and dMMR colorectal cancer

FDA granted accelerated approval to PD-1 inhibitor Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) to treat microsatellite

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE